Phase I/IIa study of the novel combination of bendamustine (B) with irinotecan (I) followed by etoposide (E) and carboplatin (C) in untreated patients (Pts) with extensive-stage small cell lung cancer (ESSCLC).

Daniel Joseph Allendorf,Rodolfo Bordani,Stefan C. Grant,Mansoor N. Saleh,Mary Jerome,Debi Miley,Alan B. Cantor,Vishnu Reddy,Francisco Robert

Phase I/IIa study of the novel combination of bendamustine (B) with irinotecan (I) followed by etoposide (E) and carboplatin (C) in untreated patients (Pts) with extensive-stage small cell lung cancer (ESSCLC).

2017

Daniel Joseph Allendorf
Rodolfo Bordani
Stefan C. Grant
Mansoor N. Saleh
Mary Jerome
Debi Miley
Alan B. Cantor
Vishnu Reddy
Francisco Robert

7591 Background: Standard therapy for ESSCLC consisting of E and a platin drug (Plat) yields a median time to progression (TTP) of 4 months (m) and overall survival (OS) of 9 m. DNA damage from B i...

Keywords:

Carboplatin
Irinotecan
Drug
Pathology
Extensive-stage small cell lung cancer
Etoposide
Oncology
standard therapy
Medicine
DNA damage
Bendamustine
Internal medicine
median time

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations